[Dyspnoea. A psychosomatic study].

E. Heim,A. Blaser,E. Waidelich

Respiration; international review of thoracic diseases

Abstract:

What problem does this paper attempt to address?

Abstract 3487: Molecular dynamic simulations of RAS family protein interactions: Mutant KRAS binding with wildtype HRAS and NRAS

Isaac Silverman,Michael S. Gerber,Aaron Shaykevich,Yitzchak F. Stein,Alexander Siegman,Sanjay Goel,Radhashree Maitra

DOI: https://doi.org/10.1158/1538-7445.am2024-3487

IF: 11.2

2024-03-31

Cancer Research

Abstract:Introduction: Mutations in the KRAS, HRAS, and NRAS genes are frequently associated with worse patient outcomes. Previous analyses of the structure and function of the associated proteins have been explored but not conclusively. The actual binding conformations of the three isoforms, especially when mutated are essential in designing inhibitory drugs. Recent studies have identified important interactions between the three isoforms that affect the oncogenic strength of the others when they are mutated. We use a bioinformatics approach to examine the modifications of the structural properties, mechanisms, and kinetic energies of eight KRAS mutants interacting with wildtype HRAS, and again with wildtype NRAS. Methodology: AlphaFold AI predicted models of KRAS, HRAS, and NRAS were downloaded from Uniprot and relevant mutations were induced using PyMOL. Pairs of KRAS mutants and either HRAS or NRAS were submitted to ClusPro for docking. PyMOL was used to separate proteins by chain identities before being repaired in GROMACS. Molecular dynamics simulations (MDS) were performed between proteins using GROMACS, a Linux based MDS software that renders a topology regulated by Newton's Laws. XmGrace was used to analyze structure, MMPBSA.py was used to derive energy calculations, and VMD was used to visualize the interaction mechanisms. Results: RMSF data indicated C-terminus residues in KRAS mutants and WT-HRAS and WT-NRAS are the most mobile in their interactions. Notably, when WT-HRAS interacts with G12R, G12S, G12V, and Q61H, its C-terminus decreases fluctuation. G13D had the greatest binding strength and strength fluctuation with WT-HRAS. G12V had the greatest binding strength with WT-NRAS. All other mutants had weaker binding with WT-NRAS than WT-KRAS. WT-HRAS had stronger binding at residue Val187 with WT-KRAS than all mutants did. WT-HRAS residues Cys184, Lys185, and Cys186 each had weaker binding energies with WT-KRAS than most mutants did. WT-KRAS residues Gln25 and Lys117 both exhibited stronger binding energy in interactions with WT-HRAS than most mutants did. WT-NRAS had stronger binding at residues Met182 and Met189 with WT-KRAS than all mutants did. Residue Pro185 in WT-NRAS did not have significant interaction with WT-KRAS, but had a strong interaction with all mutants. WT-NRAS residue Val187 had weaker binding energy with WT-KRAS than most mutants. WT-KRAS residues Tyr32 and Asp38 both exhibited weaker binding energy in interactions with WT-NRAS than most mutants did. Conclusion: MDS between KRAS mutants and WT-HRAS and WT-NRAS present notable structural modification and binding kinetics. In each KRAS mutation, different segments of the protein complexes are involved in the interaction, indicating unique inhibitory methods are required to approach each mutant. Citation Format: Isaac Silverman, Michael S. Gerber, Aaron Shaykevich, Yitzchak F. Stein, Alexander Siegman, Sanjay Goel, Radhashree Maitra. Molecular dynamic simulations of RAS family protein interactions: Mutant KRAS binding with wildtype HRAS and NRAS [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3487.

oncology
Use of a reverse cross-finger flap as a vascularized vein graft carrier in ring avulsion injuries.

D. Martin,I. Kaplan,J. Kleinert

DOI: https://doi.org/10.1016/S0363-5023(09)91124-8

Abstract:
A procedure for the simultaneous demonstration of neurosecretory and mucosubstances in tissue sections.

K. Shyamasundari,K. Rao

IF: 2.147

Acta Histochemica

Abstract:Many well known histochemical techniques have been employed to study the neurosecretory products in invertebrates and vertebrates. Among these aldehyde-fuchsin (AF) has been one of the two specific stains to demonstrate the presence of neurosecretory cells. Various counterstains have been employed with AF. However, AF is also useful in demonstrating the presence of mucosubstances or elastin. A method is described here for a simultaneous demonstration of neurosecretory substances (NSS) and mucosubstances (MS) by mercurochrome counterstaining. For this method sections of material fixed in methanol-formaldehyde-acetic acid (MFA) or alcoholic Bouin's or Susa were oxidized in 0.3% permanganate with 0.3 ml concentrated H2SO4 for 1 to 2 minutes, decolorized in 1% oxalic acid, stained in 0.5% aqueous basic fuchsin containing 1 ml concentrated HCl and 1 ml paraldehyde for 10 min and counterstained with 0.5% aqueous mercurochrome. After mercurochrome counterstaining the characteristic AF staining (purple colour) of NSS is dramatically swamped (becoming brick red) but the purple developed by MS remains unaltered in vertebrate and invertebrate material. Eosin or other counterstains do not behave in this way.
A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions

Seth P Miller,George Maio,Xiaoyu Zhang,Felix S Badillo Soto,Julia Zhu,Stephen Z Ramirez,Hening Lin

DOI: https://doi.org/10.1016/j.mcpro.2022.100268

Abstract:Active mutations in the RAS genes are found in ∼30% of human cancers. Although thought to have overlapping functions, RAS isoforms show preferential activation in human tumors, which prompted us to employ a comparative and quantitative proteomics approach to generate isoform-specific and nucleotide-dependent interactomes of the four RAS isoforms, KRAS4A, KRAS4B, HRAS, and NRAS. Many isoform-specific interacting proteins were identified, including HRAS-specific CARM1 and CHK1 and KRAS-specific PIP4K2C and IPO7. Comparing the interactomes of WT and constitutively active G12D mutant of RAS isoforms, we identified several potential previously unknown effector proteins of RAS, one of which was recently reported while this article was in preparation, RADIL. These interacting proteins play important roles as knockdown or pharmacological inhibition leads to potent inhibition of cancer cells. The HRAS-specific interacting protein CARM1 plays a role in HRAS-induced senescence, with CARM1 knockdown or inhibition selectively increasing senescence in HRAS-transformed cells but not in KRAS4B-transformed cells. By revealing new isoform-specific and nucleotide-dependent RAS interactors, the study here provides insights to help understand the overlapping functions of the RAS isoforms.
Abstract A033: KRAS codon 12 oncogenic mutations modulate protein conformation within the Switch II/Helix3 pocket

Brian Smith,Alok K. Sharma,Roger Ma,Megan Rigby,Vandana Kumari,Dominic Esposito,Dwight Nissley,Frank McCormick,Anna E. Maciag

DOI: https://doi.org/10.1158/1557-3125.ras23-a033

2023-05-01

Molecular Cancer Research

Abstract:Abstract Up to 30% of cancers harbor activating mutations in one of three RAS genes, HRAS, NRAS, or KRAS, that drive uncontrolled cellular proliferation, alter cellular metabolism, movement, differentiation, and promote cell survival and tumor immune evasion. The frequency of mutation varies across alleles and specific substitutions, with KRAS mutations occurring in roughly 81% of patients, and KRAS G12D, KRAS G12V, and KRAS G12C substitutions constituting 33%, 23%, and 12% of these cases, respectively. Cancer types exhibit characteristic preferences for RAS substitutions, the reason for which is still unknown. Oncogenic amino acid substitutions have been found to endow subtle differences in biochemical properties which cannot be explained by existing X-ray structural models. In addition, it is unclear whether these translate to distinctions in downstream signaling potential. We have initiated this study with the overall goal of understanding the effect of oncogenic mutations on the structure and dynamic properties of KRAS4b proteins in solution, and to identify any ensuing differences in effector binding behavior. Here, we present the data that identifies the structural differences between the common mutants KRAS G12D and KRAS G12C and the wildtype protein in the active conformation using solution-state NMR and Molecular Dynamics (MD) simulations, that could likely be coupled with the differing capacities to engage downstream effectors. Chemical shift perturbation (CSP) analysis demonstrates that oncogenic mutations in codon 12 of KRAS4b induce significant conformational differences when compared to the wildtype protein. These observations are localized to the Switch 2 region. We validate these observations in three-dimensional structures and reveal critical differences that are conferred by these oncogenic mutants. The solved three-dimensional solution structures of KRAS G12C/T35S/C118S-GppNHp and KRAS G12D/T35S/C118S-GppNHp reveal remarkable conformational differences within the Switch II regions, with the G12D-mutant protein adopting a relatively more flexible Switch II conformation than the G12C-mutant. Our MD simulations at a 2 μs timescale support these observations. Furthermore, we observed downstream signaling differences between KRAS G12C and KRAS G12D mutants in several cell line systems. If observed structural differences between KRAS mutants are found to directly translate to effector binding affinity, it would provide critical insight into why cancer types display preferences for RAS substitutions, and would inform RAS-targeted therapeutics. Citation Format: Brian Smith, Alok K. Sharma, Roger Ma, Megan Rigby, Vandana Kumari, Dominic Esposito, Dwight Nissley, Frank McCormick, Anna E. Maciag. KRAS codon 12 oncogenic mutations modulate protein conformation within the Switch II/Helix3 pocket [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr A033.

oncology,cell biology
Impact of novel pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines.

Tariq Arshad,Howard Donninger,Becca von Baby,Rachel Ferrill,Joe Burlison,John Trent,Geoffrey J. Clark

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.4155

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:4155 Background: Mutant-activated RAS genes are the most frequently mutated gene family associated with cancer (almost 30% of all cancers contain a mutant RAS gene). KRAS is the predominant isoform mutated in cancer and is the isoform exclusively mutated in pancreatic ductal carcinoma (PDAC). Since almost all PDAC cases harbor a mutant RAS, it is arguably the most RAS-addicted tumor type. There is now considerable evidence implicating mutant KRAS as a driver of PDAC. Recently, several mutant KRAS-targeted therapies (sotorasib and adagrasib) have been developed and show promise in PDAC patients. We have developed a direct inhibitor of RAS with a predicted unique interaction region capable of directly binding to wild-type H- and K-RAS, but which shows preferential binding for KRAS G12D and G12C mutants. This novel inhibitor disrupts the RAS effector domain and blocks the ability of RAS to signal through its effectors. Methods: We used in silico virtual library screening to identify an initial candidate inhibitor which was effective at inhibiting the 3D growth of PDAC cells without affecting their growth in 2D. Subsequent iterative rounds of medicinal chemistry was then performed to identify a series of derivatives with enhanced activity, as determined by 3D growth inhibition assays and effects on Ras signaling, as determined by Western blot analysis of phosphor-ERK, phosphor-Akt and activation of Ral A. Results: Our series of RAS inhibitors effectively block PDAC cell growth in 3D without impacting their 2D proliferation and suppress the interaction of KRAS with its effector cRAF. The inhibitors also effectively inhibit RAS signaling in mutant RAS containing PDAC cells. Since our novel compounds are predicted to bind to RAS at a different site to either AMG-510 (G12C specific inhibitor) and MRTX-1133 (G12D specific inhibitor), we tested the co-operativity of our compounds with these existing agents. Our compounds enhanced the anti-proliferative effects of both MRTX-113 and AMG-510 in mutant KRAS G12D and G12C PDAC cells, respectively. Conclusions: We have developed a series of novel RAS inhibitors that directly bind preferentially to mutant KRAS that may serve as new mutant KRAS-targeted therapeutics, and that may also have the potential to enhance the efficacy or suppress the resistance of AMG-510 and MRTX-1133.

oncology
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Hang Yang,Xinyi Zhou,Dongliang Fu,Chenqin Le,Jiafeng Wang,Quan Zhou,Xiangrui Liu,Ying Yuan,Kefeng Ding,Qian Xiao

DOI: https://doi.org/10.1002/cac2.12377

IF: 15.2825

2023-01-01

Cancer Communications

Abstract:RAS genes are the most frequently mutated oncogenes and play critical roles in the development and progression of malignancies. The mutation, isoform (KRAS, HRAS, and NRAS), position, and type of substitution vary depending on the tissue types. Despite decades of developing RAS-targeted therapies, only small subsets of these inhibitors are clinically effective, such as the allele-specific inhibitors against KRASG12C. Targeting the remaining RAS mutants would require further experimental elucidation ofRAS signal transduction, RAS-altered metabolism, and the associated immune microenvironment. This study reviews the mechanisms and efficacy of novel targeted therapies for different RAS mutants, including KRAS allele-specific inhibitors, combination therapies, immunotherapies, and metabolism-associated therapies.
Abstract PR01: Structural plasticity of KRAS oncogenic mutants – A case of misleading conclusions from GTP analogues

Alok K. Sharma,Marcin Dyba,Dominic Esposito,Bin Wang,Pedro J. Beltran,Eli Wallace,Dwight Nissley,Frank McCormick,Anna E. Maciag

DOI: https://doi.org/10.1158/1557-3125.ras23-pr01

2023-05-01

Molecular Cancer Research

Abstract:Abstract RAS mutations occur in approximately 20% of human cancers including the majority of pancreatic ductal adenocarcinoma (PDAC), half of colorectal cancers, and a third of all lung cancers. In cases of oncogenic activating RAS mutations, GTP hydrolysis is impaired, and the protein is preferentially held in the active GTP-bound state. When activated, RAS triggers multiple proliferative signaling cascades, including the MAPK/ERK and PI3K pathways, to induce cell growth, division, and differentiation. In solution, RAS exists in two interconverting GTP-bound conformational states, State 1 (inactive) and State 2 (active). State 2 is the active conformation since it binds to RAS Binding Domain (RBD) of effector proteins. Though the State 1 conformation is GTP-bound, it is unable to bind effectors and represents an inactive KRAS conformation. This State 1/State 2 equilibrium is closely coupled to the conformations (γ1 and γ2) exhibited by the γ-phosphate of GTP and its analogues. Solution-state 31P NMR spectroscopy captures and quantifies the γ1 and γ2 peaks representing State 1 and State 2 (Spoerner M et al., JBC 2010). We have initiated solution-state NMR investigation to determine the structural differences between wild-type (WT) and oncogenic mutant KRAS proteins (G12C, G12D, G12V, Q61L, and G13D) when bound to GTP and GppNHp. We quantified the State 1/State 2 equilibrium using 31P NMR. Our results show that GppNHp-bound KRAS proteins harboring oncogenic mutations differentially modulate the State 1/State 2 conformational equilibria resulting in remarkable divergence in conformational populations compared to WT protein; a notion for presence of mutation induced structural plasticity. Much work on the structural biology, biophysics and biochemistry of KRAS proteins is done when bound to the non-hydrolysable GTP analogue, GppNHp. Strikingly, our 31P NMR results show that GTP-bound KRAS elicits significant variations in State 1 and State 2 populations in comparison to GppNHp-bound proteins. These data suggest GppNHp binding induces a significant increase in the State 1 population; an observation that does not translate into GTP-bound KRAS. Our results provide additional insights into the differential binding affinities seen between WT/mutant KRAS and effector proteins (e.g., Hunter JC et al., Mol Cancer Res 2015) as well as interpretation for State 1 conformations in KRAS crystal structures when bound to mostly GppNHp and not GTP. We have also applied this 31P NMR approach to the evaluation of KRAS small molecule inhibitors that shift the population equilibrium to the State 1 (inactive) conformation in the protein-ligand complex. This demonstrates an intriguing therapeutic opportunity and novel mechanism of action that we are further exploring as part of our drug discovery pipeline. Citation Format: Alok K. Sharma, Marcin Dyba, Dominic Esposito, Bin Wang, Pedro J. Beltran, Eli Wallace, Dwight Nissley, Frank McCormick, Anna E. Maciag. Structural plasticity of KRAS oncogenic mutants – A case of misleading conclusions from GTP analogues [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr PR01.

oncology,cell biology
Exploring KRas Protein Dynamics: An Integrated Molecular Dynamics Analysis of KRas Wild and Mutant Variants

Showkat Ahmad Mir,Binata Nayak,Nada H Aljarba,Vinoth Kumarasamy,Vetriselvan Subramaniyan,Bikram Dhara

DOI: https://doi.org/10.1021/acsomega.4c02671

IF: 4.1

2024-07-01

ACS Omega

Abstract:This study employs a comprehensive approach combining protein retrieval, sequence alignment, and molecular dynamics simulations to investigate the structural dynamics and stability of wild-type KRas and its mutated variants (G12C, G12D, G12V, and G13D). The selected protein structures were retrieved from the Protein Data Bank (PDB) and prepared by using visual molecular dynamics (VMD) software. Sequence alignment using Clustal Omega provided a detailed comparison of the amino acid sequences, focusing on key mutation sites. Molecular dynamics simulations, performed with Gromacs, revealed distinct conformational changes and stability patterns in the wild-type and mutated KRas proteins over 100 ns. Clustering analysis identified higher conformational changes in the second α-helix of the mutated variants. The root-mean-square deviation (RMSD) distribution analysis showed variant-specific conformational dynamics, with G12V and G12D exhibiting slightly higher average RMSD values. Furthermore, clustering and RMSD analyses of specific amino acid residues (12, 13, 51, and 118) highlighted their roles in maintaining overall stability and influencing structural dynamics. The results indicate that mutations at positions 12 and 13 disrupt normal cycling between wild and mutated variants, leading to the persistent activation of KRas. Additionally, principal component analysis (PCA) elucidated unique conformational dynamics in mutated variants. Free energy landscape (FEL) analysis revealed alterations in the thermodynamic stability of mutated variants compared with the wild type. Overall, this study provides a detailed understanding of the structural changes associated with oncogenic mutations in KRas, offering insights crucial for targeted therapeutic strategies in KRas-driven cancers.
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Hao Chen,Jeff B. Smaill,Tongzheng Liu,Ke Ding,Xiaoyun Lu

DOI: https://doi.org/10.1021/acs.jmedchem.0c01312

IF: 8.039

2020-11-23

Journal of Medicinal Chemistry

Abstract:KRAS, the most frequently mutated oncogene, plays a predominant role in driving initiation and progression of cancers. Decades of effort to target KRAS using small molecules has been unsuccessful, causing KRAS to be considered an "undruggable" cancer target. However, this view began to change recently, as drug discovery techniques have developed several KRAS G12C allosteric inhibitors that are currently being evaluated in clinical trials. Herein we provide an in-depth analysis of the structure and binding pockets of KRAS, medicinal chemistry optimization processes, and the biological characterization of small-molecule inhibitors that directly target KRAS, including covalent allosteric inhibitors specific for the G12C mutant, GTP-competitive inhibitors targeting the nucleotide-binding site, and protein–protein interaction inhibitors that bind in the switch I/II pocket or the A59 site. Additionally, we propose potential challenges faced by these new classes of KRAS inhibitors under clinical evaluation.This article has not yet been cited by other publications.

chemistry, medicinal
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Dongsung Kim,Lorenz Herdeis,Dorothea Rudolph,Yulei Zhao,Jark Böttcher,Alberto Vides,Carlos I. Ayala-Santos,Yasin Pourfarjam,Antonio Cuevas-Navarro,Jenny Y. Xue,Andreas Mantoulidis,Joachim Bröker,Tobias Wunberg,Otmar Schaaf,Johannes Popow,Bernhard Wolkerstorfer,Katrin Gabriele Kropatsch,Rui Qu,Elisa de Stanchina,Ben Sang,Chuanchuan Li,Darryl B. McConnell,Norbert Kraut,Piro Lito

DOI: https://doi.org/10.1038/s41586-023-06123-3

IF: 64.8

2023-05-31

Nature

Abstract:Abstract KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumour growth in patients 1–7 . Whether inactive-state selective inhibition can be used to therapeutically target non-G12C KRAS mutants remains under investigation. Here we report the discovery and characterization of a non-covalent inhibitor that binds preferentially and with high affinity to the inactive state of KRAS while sparing NRAS and HRAS. Although limited to only a few amino acids, the evolutionary divergence in the GTPase domain of RAS isoforms was sufficient to impart orthosteric and allosteric constraints for KRAS selectivity. The inhibitor blocked nucleotide exchange to prevent the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. Inhibition of downstream signalling and proliferation was restricted to cancer cells harbouring mutant KRAS, and drug treatment suppressed KRAS mutant tumour growth in mice, without having a detrimental effect on animal weight. Our study suggests that most KRAS oncoproteins cycle between an active state and an inactive state in cancer cells and are dependent on nucleotide exchange for activation. Pan-KRAS inhibitors, such as the one described here, have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.

multidisciplinary sciences
Insight of the molecular mechanism of inhibitors located at different allosteric sites regulating the activity of wild type and mutant KRAS (G12)

Ye Liu,Yan Li,Guohui Li,Anhui Wang,Huiying Chu

DOI: https://doi.org/10.1016/j.abb.2024.110137

2024-08-30

Abstract:As the important hub of many cellular signaling networks, KRAS (Kirsten rat sarcoma viral oncogene homologue) has been identified as a tumor biomarker. It is the frequently mutated oncogene in human cancers, and KRAS protein activation caused by mutations, such as G12D, has been found in many human tumors tissues. Although, there are two specific allosteric sites (AS1 and AS2) on the KRAS protein that can be used as the targets for inhibitor development, the difference of regulatory mechanisms between two individual allosteric sites still not be reported. Here, using molecular dynamics simulations combined with molecular mechanics generalized born surface area (MM/GBSA) analysis, we found that both of the inhibitors, located at AS1 and AS2, were able to reduce the binding free energy between wild type, mutant KRAS (G12/D/V/S/C) and GTP remarkably, however the effect of inhibitors on the binding free energy between wild type, mutant KRAS and GDP was limited. In addition, the degree of decrease of binding free energy between KRAS and GTP caused by inhibitors at AS2 was significantly greater than that caused by inhibitors at AS1. Further analysis revealed that both inhibitors at AS1 and AS2 were able to regulate the fluctuation of Switch Ⅰ and Switch Ⅱ to expand the pocket of the orthosteric site (GTP binding site), thereby reducing the binding of KRAS to GTP. Noteworthy there was significant differences in the regulatory preferences on Switch Ⅰ and Switch Ⅱ between two type inhibitor. The inhibitor at AS2 mainly regulated Switch Ⅱ to affect the pocket of the orthosteric site, while the inhibitor at AS1 mainly expand the pocket of the orthosteric site by regulating the fluctuation of Switch Ⅰ. Our study compared the differences between two type inhibitors in regulating the KRAS protein activity and revealed the advantages of the AS2 as the small molecule drug target, aiming to provide theoretical guidance for the research of novel KRAS protein inhibitors.
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

Jameela Lokhandwala,Tracess B. Smalley,Timothy H. Tran

DOI: https://doi.org/10.3389/fonc.2024.1394702

IF: 4.7

2024-05-23

Frontiers in Oncology

Abstract:The Kirsten rat sarcoma viral oncoprotein homolog (KRAS) is currently a primary focus of oncologists and translational scientists, driven by exciting results with KRAS-targeted therapies for non-small cell lung cancer (NSCLC) patients. While KRAS mutations continue to drive high cancer diagnosis and death, researchers have developed unique strategies to target KRAS variations. Having been investigated over the past 40 years and considered "undruggable" due to the lack of pharmacological binding pockets, recent breakthroughs and accelerated FDA approval of the first covalent inhibitors targeting KRAS G12C , have largely sparked further drug development. Small molecule development has targeted the previously identified primary location alterations such as G12, G13, Q61, and expanded to address the emerging secondary mutations and acquired resistance. Of interest, the non-covalent KRAS G12D targeting inhibitor MRTX-1133 has shown promising results in humanized pancreatic cancer mouse models and is seemingly making its way from bench to bedside. While this manuscript was under review a novel class of first covalent inhibitors specific for G12D was published, These so-called malolactones can crosslink both GDP and GTP bound forms of G12D. Inhibition of the latter state suppressed downstream signaling and cancer cell proliferation in vitro and in mouse xenografts. Moreover, a non-covalent pan-KRAS inhibitor, BI-2865, reduced tumor proliferation in cell lines and mouse models. Finally, the next generation of KRAS mutant-specific and pan-RAS tri-complex inhibitors have revolutionized RAS drug discovery. This review will give a structural biology perspective on the current generation of KRAS inhibitors through the lens of emerging secondary mutations and acquired resistance.

oncology
The Target Therapy Hyperbole: "KRAS (p.G12C)"-The Simplification of a Complex Biological Problem

Massimiliano Chetta,Anna Basile,Marina Tarsitano,Maria Rivieccio,Maria Oro,Nazzareno Capitanio,Nenad Bukvic,Manuela Priolo,Alessandra Rosati

DOI: https://doi.org/10.3390/cancers16132389

2024-06-28

Abstract:Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene variations are linked to the development of numerous cancers, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). The lack of typical drug-binding sites has long hampered the discovery of therapeutic drugs targeting KRAS. Since "CodeBreaK 100" demonstrated Sotorasib's early safety and efficacy and led to its approval, especially in the treatment of non-small cell lung cancer (NSCLC), the subsequent identification of specific inhibitors for the p.G12C mutation has offered hope. However, the CodeBreaK 200 study found no significant difference in overall survival (OS) between patients treated with Docetaxel and Sotorasib (AMG 510), adding another degree of complexity to this ongoing challenge. The current study compares the three-dimensional structures of the two major KRAS isoforms, KRAS4A and KRAS4B. It also investigates the probable structural changes caused by the three major mutations (p.G12C, p.G12D, and p.G12V) within Sotorasib's pocket domain. The computational analysis demonstrates that the wild-type and mutant isoforms have distinct aggregation propensities, resulting in the creation of alternate oligomeric configurations. This study highlights the increased complexity of the biological issue of using KRAS as a therapeutic target. The present study stresses the need for a better understanding of the structural dynamics of KRAS and its mutations to design more effective therapeutic approaches. It also emphasizes the potential of computational approaches to shed light on the complicated molecular pathways that drive KRAS-mediated oncogenesis. This study adds to the ongoing efforts to address the therapeutic hurdles presented by KRAS in cancer treatment.
Structural Characterization of KRAS with a Novel Interactor, Argonaute 2

Jessica Waninger,Sunita Shankar,Ronald F. Siebenaler,Tyler S. Beyett,John J. Tesmer,Arul M. Chinnaiyan

DOI: https://doi.org/10.1096/fasebj.2018.32.1_supplement.695.6

2018-04-01

The FASEB Journal

Abstract:The RAS family of small GTPases is one of the most commonly mutated oncogenes in human cancer. Mutations usually allow the accumulation of the GTP‐bound active form of RAS, thus resulting in the aberrant activation of MAPK and PI3K pathways that control cell growth, survival, and differentiation. While much has been learned about the major downstream pathways and effectors of RAS, little progress has been made in successfully targeting mutant RAS in the treatment of cancer. Recently, we identified a functional interaction between KRAS and Argonaute 2 (AGO2), a core component of the RNA‐induced silencing complex (RISC). Further interrogation of this interaction revealed that the switch II domain of KRAS (both WT and mutant) binds to the regulatory N‐terminal (N‐t) domain of AGO2. Mutant KRAS‐AGO2 binding resulted in attenuation of the RNAi function of AGO2 by preventing microRNA unwinding, a necessary step in the formation of the mature RISC complex. In recent studies using genetically engineered mouse models, AGO2 was found to be essential for mutant KRAS driven pancreatic cancer development, foreshadowing a critical role for the KRAS‐AGO2 interaction in vivo . Further, it has previously been identified that the Tyr393 residue in AGO2 is phosphorylated by the EGFR kinase leading to decreased AGO2 function. We observed that AGO2 phosphorylated at Tyr393 disrupts its interaction with WT but not with mutant KRAS. Differences in binding of WT and mutant KRAS with or without AGO2 phosphorylation can provide valuable information on potential residues/regions in KRAS and AGO2 that can be exploited for targeting the KRAS‐AGO2 interaction, providing a basis for differential regulation of the KRAS‐AGO2 interaction through growth factor activation. In this study, we will biophysically characterize the binding interface between KRAS G12D and the N‐t fragment of AGO2. In addition, we will examine the structural changes induced by EGFR phosphorylation of AGO2. Structural characterization of this interaction will provide valuable information on potential residues/regions in KRAS and AGO2 that can be exploited for targeting this interaction in therapeutic development. Support or Funding Information HHMI NIH MSTP Training Grant This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

Dongqiang Zhao,Yu Liu,Fengchao Yi,Xia Zhao,Kui Lu

DOI: https://doi.org/10.1016/j.ejmech.2023.115698

IF: 7.088

2023-08-04

European Journal of Medicinal Chemistry

Abstract:The RAS gene, also known as the mouse sarcoma virus, includes three genes (KRAS, HRAS, and NRAS) that are associated with human tumors. Among them, KRAS has the highest incidence of mutations in cancer, accounting for around 80% of cases. At the molecular level, the RAS gene plays a regulatory role in transcription and translation, while at the cellular level, it affects cell proliferation and migration, making it crucial for cancer development. In 2021, the FDA approved AMG510, the first direct inhibitor targeting the KRAS-G12C mutation, which has shown tumor regression, prolonged survival, and low off-target activity. However, with the increase of drug resistance, a single inhibitor is no longer sufficient to achieve the desired effect on tumors. Therefore, a large number of other highly efficient inhibitors are being developed at different stages. This article provides an overview of the mechanism of action targeting KRAS-G12C in the KRASGTP-KRASGDP cycle pathway, as well as the structure-activity relationship, structure optimization, and biological activity effects of inhibitors that target the upstream and downstream pathways, or combination therapy.

chemistry, medicinal
Delineating the RAS Conformational Landscape

Mitchell I Parker,Joshua E Meyer,Erica A Golemis,Roland L Dunbrack

DOI: https://doi.org/10.1158/0008-5472.CAN-22-0804

2022-07-05

Abstract:Mutations in RAS isoforms (KRAS, NRAS, and HRAS) are among the most frequent oncogenic alterations in many cancers, making these proteins high priority therapeutic targets. Effectively targeting RAS isoforms requires an exact understanding of their active, inactive, and druggable conformations. However, there is no structural catalog of RAS conformations to guide therapeutic targeting or examining the structural impact of RAS mutations. Here we present an expanded classification of RAS conformations based on analyses of the catalytic switch 1 (SW1) and switch 2 (SW2) loops. From 721 human KRAS, NRAS, and HRAS structures available in the Protein Data Bank (206 RAS-protein cocomplexes, 190 inhibitor-bound, and 325 unbound, including 204 WT and 517 mutated structures), we created a broad conformational classification based on the spatial positions of Y32 in SW1 and Y71 in SW2. Clustering all well-modeled SW1 and SW2 loops using a density-based machine learning algorithm defined additional conformational subsets, some previously undescribed. Three SW1 conformations and nine SW2 conformations were identified, each associated with different nucleotide states (GTP-bound, nucleotide-free, and GDP-bound) and specific bound proteins or inhibitor sites. The GTP-bound SW1 conformation could be further subdivided on the basis of the hydrogen bond type made between Y32 and the GTP γ-phosphate. Further analysis clarified the catalytic impact of G12D and G12V mutations and the inhibitor chemistries that bind to each druggable RAS conformation. Overall, this study has expanded our understanding of RAS structural biology, which could facilitate future RAS drug discovery. Significance: Analysis of >700 RAS structures helps define an expanded landscape of active, inactive, and druggable RAS conformations, the structural impact of common RAS mutations, and previously uncharacterized RAS inhibitor-binding modes.
Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations

Zhenya Du,Gao Tu,Yaguo Gong,Xiangzheng Fu,Qibiao Wu,Guankui Long

DOI: https://doi.org/10.3390/molecules29061229

IF: 4.6

2024-03-11

Molecules

Abstract:The development of effective inhibitors targeting the Kirsten rat sarcoma viral proto-oncogene (KRASG12D) mutation, a prevalent oncogenic driver in cancer, represents a significant unmet need in precision medicine. In this study, an integrated computational approach combining structure-based virtual screening and molecular dynamics simulation was employed to identify novel noncovalent inhibitors targeting the KRASG12D variant. Through virtual screening of over 1.7 million diverse compounds, potential lead compounds with high binding affinity and specificity were identified using molecular docking and scoring techniques. Subsequently, 200 ns molecular dynamics simulations provided critical insights into the dynamic behavior, stability, and conformational changes of the inhibitor-KRASG12D complexes, facilitating the selection of lead compounds with robust binding profiles. Additionally, in silico absorption, distribution, metabolism, excretion (ADME) profiling, and toxicity predictions were applied to prioritize the lead compounds for further experimental validation. The discovered noncovalent KRASG12D inhibitors exhibit promises as potential candidates for targeted therapy against KRASG12D-driven cancers. This comprehensive computational framework not only expedites the discovery of novel KRASG12D inhibitors but also provides valuable insights for the development of precision treatments tailored to this oncogenic mutation.

chemistry, multidisciplinary,biochemistry & molecular biology
Targeting cancer with small-molecule pan-KRAS degraders

Johannes Popow,William Farnaby,Andreas Gollner,Christiane Kofink,Gerhard Fischer,Melanie Wurm,David Zollman,Andre Wijaya,Nikolai Mischerikow,Carina Hasenoehrl,Polina Prokofeva,Heribert Arnhof,Silvia Arce-Solano,Sammy Bell,Georg Boeck,Emelyne Diers,Aileen B. Frost,Jake Goodwin-Tindall,Jale Karolyi-Oezguer,Shakil Khan,Theresa Klawatsch,Manfred Koegl,Roland Kousek,Barbara Kratochvil,Katrin Kropatsch,Arnel A. Lauber,Ross McLennan,Sabine Olt,Daniel Peter,Oliver Petermann,Vanessa Roessler,Peggy Stolt-Bergner,Patrick Strack,Eva Strauss,Nicole Trainor,Vesna Vetma,Claire Whitworth,Siying Zhong,Jens Quant,Harald Weinstabl,Bernhard Kuster,Peter Ettmayer,Alessio Ciulli

DOI: https://doi.org/10.1126/science.adm8684

IF: 56.9

2024-09-21

Science

Abstract:Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein are highly prevalent in cancer. However, small-molecule concepts that address oncogenic KRAS alleles remain elusive beyond replacing glycine at position 12 with cysteine (G12C), which is clinically drugged through covalent inhibitors. Guided by biophysical and structural studies of ternary complexes, we designed a heterobifunctional small molecule that potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles. Compared with inhibition, KRAS degradation results in more profound and sustained pathway modulation across a broad range of KRAS mutant cell lines, killing cancer cells while sparing models without genetic KRAS aberrations. Pharmacological degradation of oncogenic KRAS was tolerated and led to tumor regression in vivo. Together, these findings unveil a new path toward addressing KRAS-driven cancers with small-molecule degraders.

multidisciplinary sciences
Targeting KRAS in cancer

Anupriya Singhal,Bob T. Li,Eileen M. O’Reilly

DOI: https://doi.org/10.1038/s41591-024-02903-0

IF: 82.9

2024-04-19

Nature Medicine

Abstract:RAS family variants—most of which involve KRAS —are the most commonly occurring hotspot mutations in human cancers and are associated with a poor prognosis. For almost four decades, KRAS has been considered undruggable, in part due to its structure, which lacks small-molecule binding sites. But recent developments in bioengineering, organic chemistry and related fields have provided the infrastructure to make direct KRAS targeting possible. The first successes occurred with allele-specific targeting of KRAS p.Gly12Cys (G12C) in non-small cell lung cancer, resulting in regulatory approval of two agents—sotorasib and adagrasib. Inhibitors targeting other variants beyond G12C have shown preliminary antitumor activity in highly refractory malignancies such as pancreatic cancer. Herein, we outline RAS pathobiology with a focus on KRAS , illustrate therapeutic approaches across a variety of malignancies, including emphasis on the 'on' and 'off' switch allele-specific and 'pan' RAS inhibitors, and review immunotherapeutic and other key combination RAS targeting strategies. We summarize mechanistic understanding of de novo and acquired resistance, review combination approaches, emerging technologies and drug development paradigms and outline a blueprint for the future of KRAS therapeutics with anticipated profound clinical impact.

biochemistry & molecular biology,cell biology,medicine, research & experimental

[Dyspnoea. A psychosomatic study].

Abstract 3487: Molecular dynamic simulations of RAS family protein interactions: Mutant KRAS binding with wildtype HRAS and NRAS

Use of a reverse cross-finger flap as a vascularized vein graft carrier in ring avulsion injuries.

A procedure for the simultaneous demonstration of neurosecretory and mucosubstances in tissue sections.

A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions

Abstract A033: KRAS codon 12 oncogenic mutations modulate protein conformation within the Switch II/Helix3 pocket

Impact of novel pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines.

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Abstract PR01: Structural plasticity of KRAS oncogenic mutants – A case of misleading conclusions from GTP analogues

Exploring KRas Protein Dynamics: An Integrated Molecular Dynamics Analysis of KRas Wild and Mutant Variants

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Insight of the molecular mechanism of inhibitors located at different allosteric sites regulating the activity of wild type and mutant KRAS (G12)

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

The Target Therapy Hyperbole: "KRAS (p.G12C)"-The Simplification of a Complex Biological Problem

Structural Characterization of KRAS with a Novel Interactor, Argonaute 2

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

Delineating the RAS Conformational Landscape

Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations

Targeting cancer with small-molecule pan-KRAS degraders

Targeting KRAS in cancer